Safety of and Adverse Reactions to the COVID-19 Vaccine Among Pregnant and Breastfeeding Women
- PMID: 40265385
- PMCID: PMC12015835
- DOI: 10.3390/medsci13020038
Safety of and Adverse Reactions to the COVID-19 Vaccine Among Pregnant and Breastfeeding Women
Abstract
Objectives: This study aimed to evaluate the incidence of adverse reactions to the COVID-19 vaccine among pregnant and breastfeeding women and identify associated demographic and clinical factors.
Methods: A cross-sectional study was conducted at a hospital in Hanoi, Vietnam, from November 2021 to March 2022. A total of 1204 participants, including 991 pregnant women beyond 13 weeks of gestation and 213 breastfeeding women, were recruited through convenience sampling. Data were collected using a self-administered questionnaire designed to capture demographic information and adverse reactions occurring within seven to 28 days post-vaccination. Statistical analyses, including chi-square tests, Fisher's exact tests, and logistic regression, were performed using Stata 16.0, with the significance set at p < 0.05.
Results: The most common adverse reactions were localized pain at the injection site (26.2%), dizziness and fatigue (19.2%), and fever below 39 °C (29.1%). Severe adverse reactions, such as a tight throat, coma, and premature birth, were rare. A multivariate analysis identified the significant factors associated with the adverse reactions, including age (aOR = 2.04 for participants aged 36-40 years), occupation (lower odds for farmers and business professionals), urban residency (aOR = 0.64), and a history of allergies (aOR = 1.59). Education level, number of children, and gestational age were not significantly associated with adverse events.
Conclusions: The findings support the safety of the COVID-19 vaccine in pregnant and breastfeeding women, with most of the adverse reactions being mild and self-limiting.
Keywords: COVID-19; adverse reactions; breastfeeding; pregnancy; vaccines.
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1. Trials. 2021. PMID: 33849629 Free PMC article.
-
SARS-CoV-2 Vaccine Willingness among Pregnant and Breastfeeding Women during the First Pandemic Wave: A Cross-Sectional Study in Switzerland.Viruses. 2021 Jun 22;13(7):1199. doi: 10.3390/v13071199. Viruses. 2021. PMID: 34206645 Free PMC article.
-
COVID-19 vaccine safety during pregnancy and breastfeeding in women with autoimmune diseases: results from the COVAD study.Rheumatology (Oxford). 2024 May 2;63(5):1341-1351. doi: 10.1093/rheumatology/kead382. Rheumatology (Oxford). 2024. PMID: 37505460
-
COVID-19 vaccination during pregnancy: coverage and safety.Am J Obstet Gynecol. 2022 Feb;226(2):236.e1-236.e14. doi: 10.1016/j.ajog.2021.08.007. Epub 2021 Aug 10. Am J Obstet Gynecol. 2022. PMID: 34389291 Free PMC article.
-
COVID-19 vaccination hesitancy in pregnant and breastfeeding women and strategies to increase vaccination compliance: a systematic review and meta-analysis.Expert Rev Vaccines. 2022 Oct;21(10):1443-1454. doi: 10.1080/14760584.2022.2100766. Epub 2022 Jul 20. Expert Rev Vaccines. 2022. PMID: 35818804
References
-
- Silvia F.-G., Laura del C.-A., Dharshini S., Jameela S., Karen L., Nana O.-L., Anoushka R., Harshitha N., Nicole S., Paul S., et al. Effectiveness and safety of COVID-19 vaccines on maternal and perinatal outcomes: A systematic review and meta-analysis. BMJ Glob. Health. 2024;9:e014247. doi: 10.1136/bmjgh-2023-014247. - DOI - PMC - PubMed
-
- Obaid A.F., Shlash A.M.J., Abdulrasol Z.A., Lafta M.A. The consequences of COVID-19 and its vaccine on pregnant and lactating mothers. Egypt. J. Immunol. 2022;29:58–74. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical